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ABSTRACT 
Background 
Progressive multiple sclerosis is a chronic autoimmune condition of unknown aetiology and 
few therapeutic options. Human exposure to aluminium has been linked with multiple 
sclerosis and affected individuals are known to excrete unusually high amounts of aluminium 
in their urine. Silicon-rich mineral waters facilitate the removal of aluminium from the body 
in urine and herein we have tested their efficacy in affecting urinary excretion of aluminium 
in individuals diagnosed with secondary progressive multiple sclerosis (SPMS). 
Methods 
Urinary excretion of aluminium and silicon, measured using transversely-heated graphite 
furnace atomic absorption spectrometry, was determined in 15 individuals diagnosed with 
SPMS over 24 weeks, a 12 week baseline period (control) followed by a 12 week treatment 
period, during which individuals consumed up to 1.5L of a silicon-rich mineral water every 
day. 
Findings 
Individuals with SPMS excreted high amounts of aluminium during the baseline period 
(135.2 nmol/mmol Crt (70.3-222.2, n=180) and females excreted significantly more 
aluminium than males. Regular drinking of a silicon-rich mineral water increased the urinary 
excretion of aluminium significantly (349.0 nmol/mmol Crt (231.7-524.7, n=180; three-way 
ANOVA, F1,13= 59.17, p-value = 0.000003) relative to the baseline period. The majority of 
individuals, 14 out of 15, excreted more aluminium (µmol/24h) following drinking of a 
silicon-rich mineral water (independent-test, p<0.05). Silicon-rich mineral waters may be an 
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effective and non-invasive therapy for the removal of aluminium from the body of 
individuals with SPMS.   (229 words) 
Keywords: Secondary progressive multiple sclerosis; aluminium and human health; silicon-
rich mineral water; urinary aluminium excretion; urinary silicon excretion, non-invasive 
therapy. 
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Highlights 
 Individuals with secondary progressive multiple sclerosis (SPMS) excrete high 
amounts of aluminium in their urine. 
 Females with SPMS excreted more aluminium than males. 
 Regular drinking of a silicon-rich mineral water increased urinary excretion of 
aluminium in males and females. 
 Silicon-rich mineral waters may be a simple and non-invasive therapy for the removal 
of aluminium from the body of individuals with SPMS. 
Research in context 
Multiple sclerosis is a burgeoning and devastating neurological condition where the cause is 
unknown and there are few if any effective therapies. Previous research suggested a role for 
human exposure to aluminium in multiple sclerosis and we have confirmed this herein by 
demonstrating that individuals, and especially females, with secondary progressive multiple 
sclerosis (SPMS) excrete high amounts of aluminium in their urine, a relative indicator of a 
high body burden of aluminium. Regular drinking of a silicon-rich mineral water facilitated 
the removal of aluminium from the body of individuals with SPMS and suggested it may be 
an effective, non-invasive future therapy.  
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1. Background 
Multiple sclerosis (MS) is a chronic, immune-mediated, demyelinating disease of the central 
nervous system of as yet unknown aetiology. While there has been progress in understanding 
the pathogenesis of MS it remains frustratingly slow (Ontaneda et al., 2017). Similarly, 
effective treatments for MS are few and far between (Thompson, 2017; Montalban et al., 
2017). It is widely accepted that MS is likely to involve both genetic and environmental 
factors acting either in isolation or together in various disease phenotypes. Human exposure 
to aluminium (Exley, 2013) has been identified as a possible contributor to MS. Individuals 
with relapsing-remitting (RRMS) and secondary progressive (SPMS) MS were shown to 
have a higher than expected body burden of aluminium (Exley et al., 2006a). The latter 
manifested as very high concentrations of aluminium in urine. A role for aluminium in MS 
might be expected based upon the known association of the metal with myelin (Verstraeten et 
al., 1997) and oligodendrocytes in animal models of aluminium intoxication (Golub and 
Tarrara, 1999). Indeed recent, limited, clinical studies have shown increased urinary 
excretion of aluminium in MS following chelation with EDTA (Fulgenzi et al., 2012; Zanella 
and di Sarsina, 2013; Fulgenzi et al., 2015). Aluminium’s role in the pathogenesis of MS and 
the progression of the disease is currently unknown but it may be related to aluminium’s 
activity as a pro-oxidant (Exley, 2004) or as an adjuvant capable of inducing a form of 
autoimmunity in affected tissues (Exley et al., 2009). Both of these potential mechanisms of 
aluminium toxicity have implications for myelin breakdown in MS. 
We have pioneered silicon-rich mineral waters as non-invasive methods to facilitate the 
urinary excretion of aluminium in both health and disease (Exley et al., 2006b). Individuals 
have been shown to excrete significant amounts of aluminium following regular drinking of 
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1.0-1.5L of a silicon-rich mineral water and in individuals with Alzheimer’s disease (AD) 
this resulted in a lowering of their body burden of aluminium over only 12 weeks 
(Davenward et al., 2013). Herein we have recruited individuals with SPMS and used urinary 
excretion of aluminium to establish their body burdens of aluminium both before and after 
regular drinking of a silicon-rich mineral water for 12 weeks. We show that this is an 
effective strategy for lowering the body burden of aluminium in SPMS. 
 
2. Methods 
2.1 Participants 
Participants, 8 females and 7 males, mean age 63 (range 52-73), were recruited from 
Neurology at the University Hospital of North Staffordshire. Recruits were diagnosed as 
SPMS according to revised Lublin-Rheingold criteria (Lublin et al.,2014). Exclusion criteria 
included individuals with urinary infections or impaired renal function and participants using 
disease-modifying treatments including aluminium-based antacids. None of the participants 
in the study were current smokers as smoking is known to contribute to the body burden of 
aluminium (Exley et al., 2006c). Recruits were assessed at the beginning of the trial 
according to the Expanded Disability Status Scale (EDSS) and all scored between 4 and 7. 
All participants gave written consent and the trial received NREC approval (14-YH-1115). 
2.2 Protocol 
The primary objective of the study was to establish if regular drinking of a silicon-rich 
mineral water could be an effective non-invasive therapy to reduce the body burden of 
aluminium in individuals with SPMS. Participants were encouraged to live their lives 
normally during the 24 weeks of the study with the only differences being the collection of 
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their urine samples (see details below) and, during weeks 13 to 24 inclusive, the addition of a 
silicon-rich (ca 35 mg/L as silicic acid) mineral water to their everyday diet. The latter was 
provided by the Malaysian mineral water company Spritzer and participants were encouraged 
to drink up to 1.5L daily.  
The study was conducted over two consecutive 12 week periods. The baseline period (weeks 
1-12) was used to estimate normal levels of urinary aluminium and silicon excretion while 
the treatment period (weeks 13-24) was used to establish how regular drinking of a silicon-
rich mineral water affected urinary aluminium and silicon excretion. For Monday to Friday of 
weeks, 1, 12, 13 and 24 participants collected 24h urine samples while for weeks 2-11 and 
14-23 participants collected their first urine of the day on the Wednesday of that week.  
2.3 Sample collection, storage and measurements 
Participants were given instructions, to help reduce issues relating to potential contamination, 
on collection of urine samples and they were provided with pristine, acid-washed, labelled 
containers. Urine samples were stored in biohazard bags in participants’ domestic 
refrigerators prior to their collection and transport to Keele University for processing. Upon 
arrival in the Bioinorganic Chemistry Laboratory the total volumes of the 24h samples were 
measured and thereafter all urine samples were thoroughly mixed and sampled for subsequent 
creatinine analyses using the Jaffe reaction. Further sub-samples were then stored frozen 
prior to their microwave-assisted acid digestion and analysis of total aluminium and silicon 
by transversely heated graphite furnace atomic absorption spectrometry (TH GFAAS) 
(Davenward et al., 2013).  
2.4 Statistical analyses 
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Data are expressed as medians and interquartile range (IQR), for the baseline (weeks 1-12) 
and treatment period (weeks 13-24) both for all patients together and separately for each 
patient. Data are skewed and for further statistical analysis data were log(x+10) transformed 
to fulfil normal distribution. Differences in urinary excretion of aluminium and silicon 
between females and males were analysed with an independent t-test. When we compared 
first and last week of each baseline and treatment period a paired t-test was used.  
To detect a possible influence of the silicon-rich mineral water therapy on urinary excretion 
of aluminium and silicon a nested three-way ANOVA with the factors, week nested in 
treatment and the additional factor gender was performed. The factor treatment encodes for 
the baseline period and the silicon-rich mineral water therapy, the factor week expresses 
possible changes in urinary excretion over the 12 weeks of each period and the factor gender 
expresses possible differences in urinary excretion of females and males. Additional post-hoc 
tests were performed using Bonferroni-correction. 
Furthermore to analyse the relationship of aluminium and silicon a Pearson-correlation and a 
linear regression analysis of log-transformed data was performed and a p-value smaller than 
0.05 was considered as statistically significant. For statistical analysis SPSS Statistics v.22 
(IBM Analytics, Armonk, NY, USA) and for additional analysis and figures R Studio 
(Version 1.0.153 – © 2009-2017 RStudio, Inc.) was used. 
 
3.Results 
3.1 Urinary excretion of aluminium (creatinine-corrected data) 
Median urinary excretion of aluminium during the baseline period (1-12 weeks) ranged from 
51.8 (39.5-61.8) to 326.1 (201.0-582.7) nmol/mmol Crt (median + IQR, n=15) (Table 1). The 
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median for all 15 participants over the 12 weeks was 135.2 nmol/mmol Crt (70.3-222.2, 
n=180). Females, with an overall median concentration of 169.7 nmol/mmol Crt (149.5-
222.1, n=8) excreted significantly more aluminium than males (102.0 nmol/mmol Crt, 65.3-
152.4, n=7) (independent t-test, t(13)=2.52, p=0.026). There was no significant difference in 
urinary excretion of aluminium between the start (week 1), 130.1 nmol/mmol Crt (72.4-
299.6, n=15) and end (week 12), 83.7 nmol/mmol Crt (67.2-148.0, n=15) of the baseline 
period (paired t-test, t(14)=1.37, p=0.194) (Figure 1).   
Median urinary excretion of aluminium during the treatment period (13-24 weeks) ranged 
from 140.5 (124.5-188.7) to 1081.4 (393.2-2270.8) nmol/mmol Crt. (median +IQR, n=15) 
(Table 1). The median for all 15 participants over the 12 weeks was 349.0 nmol/mmol Crt 
(231.7-524.7, n=180). Females excreted more aluminium (394.7 nmol/mmol Crt, 354.9-
417.8, n=8) than males, (296.0 nmol/mmol Crt, 270.3-436.3, n=7), but the difference was not 
statistically significant (independent t-test, t(13)=1.75, p=0.103). There was no significant 
difference in urinary excretion of aluminium between the start (week 13), 327.7 (47.1-411.5, 
n=15) and end (week 24), 389.9 (184.6-513.7, n=15) of the treatment period (paired t-test, 
t(14)=-1.66, p=0.119)(Figure 1). 
The urinary excretion of aluminium during the treatment period was higher than during the 
baseline period (Table 1; Figure 2) (three-way ANOVA, F1,13= 59.17, p-value = 0.000003). 
In the overall model we also observed significantly different urinary excretion of aluminium 
between females and males (three-way ANOVA, F1,13= 15.58, p-value = 0.002). Post-Hoc 
tests showed significant differences between females and males in week 4, 8, 9, 15 and 16. 
The within-factor ‘week’ (nested in treatment) had no significant influence on aluminium 
concentration in urine (three-way ANOVA, F1,13= 1.67, p-value = 0.085). 
3.2 Urinary excretion of silicon (creatinine-corrected data) 
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Median urinary excretion of silicon during the baseline period (1-12 weeks) ranged from 44.5 
(39.3-73.6) to 192.7 (129.9-363.2) mol/mmol Crt. (median +IQR, n=15) (Table 2). The 
median for all 15 participants over the 12 weeks was 81.3 mol/mmol Crt. (47.9-118.6, 
n=180). Females, with an overall median concentration of 105.2 mol/mmol Crt (86.8-113.5, 
n=8) excreted significantly more silicon than males (69.2 mol/mmol Crt, 45.1-75.6, n=7) 
(independent t-test, t(13)=4.13, p= 0.001). There was no significant difference in urinary 
excretion of silicon between the start (week 1), 92.8 mol/mmol Crt (74.9-135.3, n=15) and 
end (week 12), 82.7 mol/mmol Crt (41.8-114.7, n=15) of the baseline period (paired t-test, 
t(14)=2.04, p=0.06)(Table 2; Figure 3).  
Median urinary excretion of silicon during the treatment period (13-24 weeks) ranged from 
102.4 (83.7-134.2) to 349.3 (317.7-448.6) mol/mmol Crt. (median +IQR, n=15) (Table 2). 
The median for all 15 participants over the 12 weeks was 221.5 mol/mmol Crt (134.8-332.7, 
n=180). Females, with an overall median concentration of 270.0 mol/mmol Crt (246.8-
324.1, n=8) excreted significantly more silicon than males (140.6 mol/mmol Crt, 131.6-
201.4, n=7) (independent t-test, t(13)=4.05, p= 0.001). There was no significant difference in 
urinary excretion of silicon between the start (week 13), 229.2 (142.9-331.7, n=15) and end 
(week 24), 156.9 (128.5-310.7, n=15) of the treatment period (paired t-test, t(14)=1.2, 
p=0.249)(Table 2; Figure 3). 
The urinary excretion of silicon during the treatment period was higher than during the 
baseline period (three-way ANOVA, F1,13= 220.19, p-value < 0.001) (Table 2; Figure 4). The 
factor ‘gender’ was significant for urinary excretion of silicon during the treatment period 
(three-way ANOVA, F1,13= 24.19, p-value = 0.000281). Post-Hoc tests showed significant 
differences between females and males in week 1,2,4,8, 15, 16, 18 and 19. The within-factor 
‘week’ had also a significant influence on urinary excretion of silicon (three-way ANOVA, 
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F1,13= 1.89, p-value = 0.045), though this effect was not proven in a post-hoc test neither for 
the baseline period (p=0.415) nor the treatment period (p=0.495). 
3.3 Correlations between urinary excretion of silicon and aluminium (Crt-corrected data) 
The urinary excretion of aluminium was positively correlated with the urinary excretion of 
silicon for all participants over the full 24 weeks of the trial (Figure 5). In females the 
relationship was more highly correlated in the treatment as compared to the baseline period 
(Figure 6A,B). In males this relationship was very weak in the baseline period becoming 
stronger during the treatment period (Figure 6C,D). 
3.4 24h aluminium data for weeks 1, 12(baseline), 13 and 24(treatment) 
The amount of aluminium excreted during the baseline period (data for weeks 1 and 12 
combined) ranged from 0.85 (0.6-1.3) to 2.98 (2.3-4.2) µmol/24h (median+IQR, n=10). This 
increased from 0.23 (0.2-0.4) to 8.08 (8.0 – 8.4) for week 13 (Table 3) and 3.01 (3.0 – 3.3) to 
10.77 (10.3 – 13.1) µmol/24h (median+IQR, n=5) for week 24 (Table 4). Increases in the 
amount of aluminium excreted in week 13 and week 24 relative to baseline were significant 
for 10 and 14 individuals respectively (independent-test, p<0.05) (Tables 3 & 4; Figures 7 & 
8). In 6 individuals there were significant differences (independent t-test, p<0.05) in the 
amount of aluminium excreted between week 13 and week 24 with 1 out of the 6 individuals 
showing a statistically significant (independent t-test, p<0.05) fall in the amount of 
aluminium excreted during the 12 weeks of the treatment period (Table 5; Figure 8).   
3.5 Qualitative observations 
None of the 15 individuals who took part in the study experienced any relapses during the 24 
weeks of the trial. Neither did their EDSS scores change during this period. 
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4. Discussion 
Participants were fully compliant with the study and urine samples (spot and 24h) were 
obtained as required from all 15 participants for the duration of the 24 week study. We have 
presented the first comprehensive data set for the urinary excretion of aluminium and silicon 
in MS over an extended time period.  
The data for aluminium demonstrate wide variability across the baseline period (weeks 1-12) 
with the median + IQR (135.2 nmol/mmol Crt + 70.3-222.2, n=180) reflecting significant 
inter-subject variability (Table 1; Figure 2). However, within such variability and for a 
somewhat limited number of individuals we were still able to discriminate statistically 
significantly (independent t-test, t(13)=2.52, p=0.026) higher excretion of aluminium in 
females (169.7 nmol/mmol Crt + 149.5-222.1, n=8) than males (102.0 nmol/mmol Crt + 
65.3-152.4, n=7). This suggests that this relationship, females exhibiting increased urinary 
excretion of aluminium, would be even stronger for a larger cohort of participants. While 
there are few comparative data within the scientific literature urinary excretion of aluminium 
was previously measured using single spot urine samples taken from 10 individuals (7 female 
and 3 male) diagnosed with SPMS (Exley et al., 2006a) and the computed median of this 
cohort, 99.2 nmol/mmol Crt, was similar to that obtained herein. It is also noteworthy that in 
the previous study the 3 lowest values, 17.6, 75.1 and 85.2 nmol/mmol Crt, were those of the 
3 male subjects. In the age and gender-matched control population of the previous study the 
median urinary excretion of aluminium was 37.6 nmol/mmol Crt which was significantly 
lower than the median for the SPMS group (P<0.001) and adds to the conclusion herein, 
where the median is 135.2 nmol/mmol Crt, that individuals with SPMS, and females in 
particular, excrete unusually high amounts of aluminium in their urine.  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
The data for urinary excretion of aluminium during the treatment period (weeks 13-24), when 
all individuals were drinking up to 1.5L of a silicon-rich mineral water every day, also 
showed a high degree of inter-subject variability with the median excretion rising to 349.0 
nmol/mmol Crt (231.7-524.7, n=180) which was a statistically significant increase relative to 
the baseline period (three-way ANOVA, F1,13= 59.17, p-value = 0.000003) (Table 1; Figure 
2). While females once again excreted more aluminium than males the increase was not 
statistically significant for the treatment period (independent t-test, t(13)=1.75, p=0.103). 
Increased urinary excretion of aluminium during the treatment period paralleled the 
statistically significant increase in urinary silicon excretion between the baseline (81.3 
mol/mmol Crt + 47.9-118.6, n=180) and treatment (221.5 mol/mmol Crt + 134.8-332.7, 
n=180) periods (three-way ANOVA, F1,13= 220.19, p-value < 0.001) (Table 2; Figure 4). 
Urinary excretion of silicon in females was statistically higher than males in both the baseline 
and treatment periods and so, similar to the overall picture, suggested a role for silicon in the 
urinary excretion of aluminium. Regression analyses confirmed a positive relationship 
between urinary excretion of aluminium and silicon and especially so in females (Figures 5 & 
6). In exploring this relationship further we used the 24h urine data for weeks 1, 12, 13 and 
24 to investigate how drinking a silicon-rich mineral water influenced how much aluminium 
was excreted by each of the 15 participants. Data for weeks 1 and 12 were not significantly 
different and so were pooled to give a single value for baseline excretion. When baseline data 
were compared with data for week 13, thus the first week drinking the silicon-rich mineral 
water, it was found that there were statistically significant increases in the amount of 
aluminium excreted in 10 of the 15 participants (Table 3; Figure 7). Similarly for week 24, 
when participants had been drinking the silicon-rich mineral water for 12 weeks, 14 out of 15 
participants showed statistically significant higher amounts of aluminium in their urine 
relative to the baseline period (Table 4; Figure 8). While all data, both creatinine-corrected 
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and 24h, showed that the excretion of aluminium during the baseline period was 
homogenous, unaffected by week, we were interested to know if such was also true between 
the beginning (week 13) and end (week 24) of the treatment period. When urinary excretion 
in week 13 was compared with week 24 for each individual we found a fall in urinary 
aluminium excretion in 3 individuals though such was only statistically significant in 1 
(female) patient (Table 5; Figure 9). In the only other published long term study of the 
excretion of aluminium following drinking silicon-rich mineral waters individuals with a 
diagnosis of Alzheimer’s disease showed a statistically significant fall in urinary aluminium 
excretion over a 12 week period. This was interpreted as evidence that longer term drinking 
of a silicon-rich mineral water would begin to reduce the body burden of aluminium as 
estimated using urinary aluminium excretion. Herein in SPMS we observed preliminary 
evidence that this was happening in some individuals. A longer study over months and years 
would help to test the validity of this hypothesis. It is of note that the median urinary 
excretion of aluminium in week 12 of the previous AD study (Davenward et al., 2013) was 
64.8 nmol/mmol Crt compared to 389.9 nmol/mmol Crt in SPMS. This may be further 
evidence that the body burden of aluminium in MS may be significantly higher than it is in 
AD and as such it may take considerably longer to lower the body burden of aluminium in 
MS through regular drinking of a silicon-rich mineral water. Only, as suggested previously, a 
longer-term study will help to resolve this question. 
We are able to conclude that individuals with SPMS excrete an unusually high amount of 
aluminium in their urine and this confirms the results of a previous much smaller study. 
Regular drinking of a silicon-rich mineral water increased their urinary excretion of 
aluminium which suggested that individuals with SPMS have a high body burden of 
aluminium. Drinking a silicon-rich mineral water for 12 consecutive weeks provided limited 
evidence that such could help individuals in reducing their body burden of aluminium if this 
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was continued for months and years thereafter. Females had a higher content of aluminium in 
their urine than males which suggested a higher body burden of aluminium in females. The 
incidence of MS is also higher in females which may begin to suggest that the body burden of 
aluminium predisposes females to the disease. Metabolomic profiling may in the future 
reveal further gender differences in MS (Villoslada et al., 2017) some of which may also shed 
some light on how aluminium is handled by the body in MS. If human exposure to 
aluminium has a role to play in the aetiology of MS then regular drinking of a silicon-rich 
mineral water may act as a simple, non-invasive therapy for the removal of aluminium. 
(3065 words) 
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Figure Legends 
Figure 1 Comparison of urinary aluminium excretion in control and treatment periods. 
Boxplot of urinary aluminium excretion (nmol/mmol Crt) for the first (n=15) and last weeks 
(n=15) of the baseline (weeks 1-12) and treatment (weeks 13-24) periods respectively. There 
were no significant differences in aluminium excretion between the first and last weeks of 
either the baseline or the treatment period, (paired t-test, p>0.05, n=15).  
Figure 2 Urinary aluminium excretion over the full 24 weeks of the study. 
Boxplots of urinary aluminium excretion (nmol/mmol Crt) from week 1 to week 24 
(nfemales=8; nmales=7). There was a significant increase in aluminium excretion between the 
baseline (weeks 1-12) and treatment (weeks 13-24) periods (p<0.001).  
Figure 3 Comparison of urinary silicon excretion in control and treatment periods. 
Boxplot of urinary silicon excretion (mol/mmol Crt) for the first (n=15) and last weeks 
(n=15) of the baseline (weeks 1-12) and treatment (weeks 13-24) periods respectively. There 
were no significant differences in silicon excretion between the first and last weeks of either 
the baseline or the treatment period, (paired t-test, p>0.05, n=15).  
Figure 4 Urinary silicon excretion over the full 24 weeks of the study. 
Boxplots of urinary silicon excretion (mol/mmol Crt) from week 1 to week 24 (nfemales=8; 
nmales=7). There was a significant increase in silicon excretion between the baseline (weeks 1-
12) and treatment (weeks 13-24) periods (p<0.001).  
Figure 5 The relationship between urinary aluminium and silicon excretion for all 
participants. 
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Scatter-plot of log-transformed aluminium and silicon excretion data (Crt-corrected) for all 
15 participants over the full 24 weeks (n=180).  
Figure 6A-D Relationships between urinary excretion of aluminium and silicon based on 
gender and study period. 
Scatter-plots of log-transformed aluminium and silicon excretion data (Crt-corrected) for 
females (n=96) and males (n=84) for separate baseline (weeks 1-12) and treatment (weeks 
13-24) periods.  
Figure 7 Comparison of amount of aluminium excreted in control and the first week of the 
treatment period. 
Boxplots of urinary aluminium excretion (mol/24h) for all patients for the baseline period 
(week 1 and 12 combined, n=10) compared to the first week of the treatment period (week 
13, n=5).  
 
Figure 8 Comparison of amount of aluminium excreted in control and the last week of the 
treatment period. 
Boxplots of urinary aluminium excretion (mol/24h) for all patients for the baseline period 
(week 1 and 12 combined, n=10) compared to the last week of the treatment period (week 24, 
n=5).  
Figure 9 Comparison of amount of aluminium excreted in the first and last weeks of the 
treatment period. 
Boxplots of urinary aluminium excretion (mol/24h) for all patients and comparing the first 
week (week 13, n=5) and the last week (week 24, n=5) of the treatment period.  
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Table1. Median and IQR of aluminium concentration [nmol/mmol Crt] in urine of SPMS 
patients before (week 1-12) and after the treatment (week 13-24) with silicon-rich mineral 
water, N=12. 
Patient ID Baseline (Wks 1-12) Treatment (Wks 13-24) 
F001 164.5 (120.9-210.8) 1081.4 (393.2-2270.8) 
F003   99.2 (73.6-150.5)   400.4 (131.0-913.1) 
F006 175.0 (113.3-239.5)   353.8 (221.1-647.6) 
F009 152.1 (84.5-252.6)   435.3 (341.8-684.8) 
F012 203.4 (94.1-306.1)   390.2 (312.1-575.1) 
F013 240.8 (189.5-366.0)   356.0 (304.2-486.3) 
F015 326.1 (201.0-582.7)   399.2 (279.4-682.8) 
F016 146.9 (76.8-202.2)   328.3 (279.7-550.7) 
M002   89.5 (69.1-133.8)   436.2 (264.0-544.9) 
M004   51.80 (39.5-61.8)   452.95 (335.5-511.1) 
M005 103.6 (59.8-128.2)   388.5 (156.1-468.3) 
M007 102.0 (69.5-131.1)   296.0 (251.3-500.7) 
M010 232.0 (88.1-281.0)   270.3 (229.6-387.7) 
M011   65.3 (49.9-128.4)   140.5 (124.5-188.7) 
M014 152.4 (92.0-225.4)   271.2 (196.2-332.7) 
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Table 2. Median and IQR of silicon concentration [mol/mmol Crt] in urine of SPMS 
patients before (week 1-12) and after the treatment (week 13-24) with silicon-rich mineral 
water N=12. 
   
Patient ID Baseline (Wks 1-12) Treatment (Wks 13-24) 
F001 113.7 (66.6-169.0) 349.3 (317.7-448.6) 
F003   84.1 (57.5-137.0) 242.9 (134.2-535.0) 
F006 100.5 (84.8-118.1) 262.8 (168.8-386.7) 
F009 113.4 (81.9-140.6) 313.8 (264.4-473.0) 
F012 109.9 (67.7-173.3) 334.4 (219.8-440.1) 
F013   89.4 (43.8-114.2) 250.6 (175.3-294.5) 
F015 192.7 (129.9-363.2) 277.3 (179.2-382.6) 
F016   83.2 (53.7-142.2) 170.9 (129.8-402.6) 
M002   44.5 (39.3-73.6) 230.6 (144.2-374.5) 
M004   69.2 (57.3-94.3) 140.6 (113.9-285.5) 
M005   48.3 (33.8-76.0) 131.6 (112.6-311.3) 
M007   77.7 (48.7-108.2) 201.4 (141.5-238.9) 
M010   75.6 (42.8-114.0) 195.4 (134.9-250.2) 
M011   75.6 (23.5-88.5) 134.7 (73.6-150.5) 
M014   45.1 (14.3-69.2) 102.4 (83.7-134.2) 
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Table 3 Median and IQR of urinary Al excretion (mol/24h) for all patients for the baseline 
period (week 1 and 12 combined, n=10) compared to the first week of the treatment period 
(week 13, n=5). 
 
Baseline - Week 13 Median IQR p-value Effect 
F001 
baseline 0.86 0.4-1.5 
0.001 ↑ 
treatment 4.54 2.0-4.7 
F003 
baseline 0.92 0.5-1.4 
0.466 ↑ 
treatment 1.32 1.3-1.9 
F006 
baseline 1.09 0.8-1.5 
0.015 ↓ 
treatment 0.38 0.3-0.5 
F009 
baseline 0.85 0.6-1.3 
0.815 ↓ 
treatment 0.23 0.2-0.4 
F012 
baseline 2.98 2.3-4.2 
0.002 ↑ 
treatment 8.08 8.1-8.4 
F013 
baseline 2.02 1.1-4.1 
0.005 ↑ 
treatment 6.92 6.8-7.0 
F015 
baseline 1.62 0.3-3.1 
0.001 ↑ 
treatment 4.96 4.9-5.4 
F016 
baseline 0.86 0.5-1.2 
<0.001 ↑ 
treatment 2.24 2.2-2.9 
M002 
baseline 1.02 0.8-1.1 
0.140 ↑ 
treatment 1.15 1.1-1.2 
M004 baseline 0.87 0.6-1.3 0.001 ↑ 
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treatment 3.05 2.2-4.6 
M005 
baseline 1.16 0.8-1.7 
0.789 ↓ 
treatment 0.85 0.8-1.5 
M007 
baseline 1.38 1.2-1.6 
<0.001 ↑ 
treatment 5.21 3.6-6.8 
M010 
baseline 2.60 1.1-3.9 
0.013 ↑ 
treatment 5.67 4.5-6.9 
M011 
baseline 2.85 2.2-3.1 
<0.001 ↑ 
treatment 5.89 4.8-7.0 
M014 
baseline 1.71 1.0-2.0 
<0.001 ↑ 
treatment 7.26 6.8-7.7 
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Table 4 Median and IQR of urinary Al excretion (mol/24h) for all patients for the baseline 
period (week 1 and 12 combined, n=10) compared to the last week of the treatment period 
(week 24, n=5). 
 
Baseline - Week 24 Median IQR p-value Effect 
F001 
baseline 0.86 0.4-1.5 
<0.001 ↑ 
treatment 3.99 3.4-4.5 
F003 
baseline 0.92 0.5-1.4 
0.046 ↑ 
treatment 3.60 1.5-4.5 
F006 
baseline 1.09 0.8-1.5 
<0.001 ↑ 
treatment 7.11 5.4-8.2 
F009 
baseline 0.85 0.6-1.3 
<0.001 ↑ 
treatment 10.77 10.3-13.1 
F012 
baseline 2.98 2.3-4.2 
0.942 ↓ 
treatment 3.07 2.3-3.2 
F013 
baseline 2.02 1.1-4.1 
0.030 ↑ 
treatment 5.06 4.7-7.0 
F015 
baseline 1.62 0.3-3.1 
0.016 ↑ 
treatment 4.13 4.0-4.7 
F016 
baseline 0.86 0.5-1.2 
<0.001 ↑ 
treatment 3.86 2.8-4.5 
M002 
baseline 1.02 0.8-1.1 
<0.001 ↑ 
treatment 5.32 5.0-5.8 
M004 baseline 0.87 0.6-1.3 <0.001 ↑ 
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treatment 8.50 6.4-9.9 
M005 
baseline 1.16 0.8-1.7 
0.004 ↑ 
treatment 3.01 3.0-3.3 
M007 
baseline 1.38 1.2-1.6 
<0.001 ↑ 
treatment 4.90 3.7-5.1 
M010 
baseline 2.60 1.1-3.9 
0.039 ↑ 
treatment 3.42 3.4-4.8 
M011 
baseline 2.85 2.2-3.1 
0.017 ↑ 
treatment 4.97 3.0-5.4 
M014 
baseline 1.71 1.0-2.0 
<0.001 ↑ 
treatment 4.75 4.5-5.5 
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Table 5 Median and IQR of urinary Al excretion (mol/24h) for all patients and comparing 
the first week (week 13, n=5) and the last week (week 24, n=5) of the treatment period.  
 
 
week 1 week 2 
 
  
 
Median IQR Median IQR p-value   
F001 4.5 2.0-4.7 4.0 3.4-4.5 0.816 ↓ 
F003 1.3 1.3-1.9 3.6 1.5-4.5 0.106 ↑ 
F006 0.4 0.3-0.5 7.1 5.4-8.2 <0.001 ↑ 
F009 0.2 0.2-0.4 10.8 10.3-13.1 0.003 ↑ 
F012 8.1 8.1-8.4 3.1 2.3-3.2 <0.001 ↓ 
F013 6.9 6.8-7.0 5.1 4.7-7.0 0.295 ↓ 
F015 5.0 4.9-5.4 4.1 4.0-4.7 0.057 ↓ 
F016 2.2 2.2-2.9 3.9 2.8-4.5 0.080 ↑ 
M002 1.2 1.1-1.2 5.3 5.0-5.8 <0.001 ↑ 
M004 3.0 2.2-4.6 8.5 6.4-9.9 0.012 ↑ 
M005 0.9 0.8-1.5 3.0 3.0-3.3 0.007 ↑ 
M007 5.2 3.6-6.8 4.9 3.7-5.1 0.800 ↓ 
M010 5.7 4.5-6.9 3.4 3.4-4.8 0.117 ↓ 
M011 5.9 4.8-7.0 5.0 3.0-5.4 0.252 ↓ 
M014 7.3 6.8-7.7 4.8 4.5-5.5 0.142 ↓ 
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Fig. 9 
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